Christopher S Lee

发表

Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018

I. Abraham, B. Ortiz, K. MacDonald, 2019, Expert review of clinical immunology.

Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic re

I. Abraham, B. Ortiz, K. MacDonald, 2019 .

A pharmacoepidemiological study of the multi-level determinants, predictors, and clinical outcomes of biosimilar epoetin alfa for renal anaemia in haemodialysis patients: background and methodology of the MONITOR-CKD5 study

G. London, L. Gesualdo, C. Combe, 2013, Internal and Emergency Medicine.

No margin for non-adherence: Probabilistic kaplan-meier modeling of imatinib non-adherence and treatment response in CML (ADAGIO study).

S. De Geest, I. Abraham, K. MacDonald, 2021, Leukemia research.

Modelling of blood pressure and total cardiovascular risk outcomes after second-line valsartan therapy: the BSCORE study.

Yu-ming Shen, R. Lins, I. Abraham, 2011, Archives of cardiovascular diseases.

Background and methodology of MONITOR-GCSF, a pharmaco-epidemiological study of the multi-level determinants, predictors, and clinical outcomes of febrile neutropenia prophylaxis with biosimilar granulocyte-colony stimulating factor filgrastim.

M. Aapro, P. Gascón, H. Ludwig, 2011, Critical reviews in oncology/hematology.

"Real-life" Effectiveness Studies of Omalizumab in Adult Patients with Severe Allergic Asthma: Meta-analysis.

I. Abraham, K. MacDonald, A. Alhossan, 2017, The journal of allergy and clinical immunology. In practice.

Meta-Analysis of Same-Day Pegfilgrastim Administration Stratified by Myelotoxic Febrile Neutropenia Risk and Tumor Type

I. Abraham, Jennifer R Martin, A. McBride, 2022, Journal of the advanced practitioner in oncology.

‘Real-world’ effectiveness of omalizumab in adults with severe allergic asthma: a meta-analysis

I. Abraham, K. MacDonald, A. Alhossan, 2020, Expert review of clinical immunology.

Benefits and Harms of Omalizumab Treatment in Adolescent and Adult Patients With Chronic Idiopathic (Spontaneous) Urticaria: A Meta-analysis of “Real-world” Evidence

J. Bernstein, K. Denhaerynck, I. Abraham, 2019, JAMA dermatology.

Ex Ante Economic Evaluation of Arg389 Genetically Targeted Treatment with Bucindolol versus Empirical Treatment with Carvedilol in NYHA III/IV Heart Failure

B. Erstad, J. Karnes, M. Slack, 2020, American Journal of Cardiovascular Drugs.

Effectiveness of Amlodipine-Valsartan Single-Pill Combinations: Hierarchical Modeling of Blood Pressure and Total Cardiovascular Disease Risk Outcomes (the EXCELLENT Study)

Yu-ming Shen, R. Lins, I. Abraham, 2011, The Annals of pharmacotherapy.

Effectiveness of Valsartan for Treatment of Hypertension: Patient Profiling and Hierarchical Modeling of Determinants and Outcomes (the Preview Study)

K. Denhaerynck, I. Abraham, C. Hermans, 2009, The Annals of pharmacotherapy.

Real-world effectiveness of valsartan on hypertension and total cardiovascular risk: review and implications of a translational research program

I. Abraham, C. Hermans, K. MacDonald, 2011, Vascular health and risk management.

Hierarchical linear and logistic modeling of outcomes of antihypertensive treatment in elderly patients: findings from the PREVIEW study.

I. Abraham, C. Hermans, P. Van der Niepen, 2010, Archives of gerontology and geriatrics.

“Later, lazier, and unluckier”: a heuristic profile of high vulnerability is an independent predictor of uncontrolled blood pressure (the PREVIEW study)

I. Abraham, C. Hermans, P. Van der Niepen, 2010, International journal of general medicine.

Efficacy of Same-Day Vs. Next-Day Pegfilgrastim for the Prevention of Chemotherapy-Induced (Febrile) Neutropenia (CIN/FN): A Meta-Analysis

I. Abraham, Jennifer R Martin, A. McBride, 2015 .

‘Real‐life’ effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review

I. Abraham, H. Kutbi, A. Alhossan, 2016, Allergy.

Meta-Analysis of Same-Day Pegfilgrastim Administration Stratified by Myelotoxic Febrile Neutropenia Risk and Tumor Type

I. Abraham, Jennifer R Martin, A. McBride, 2022, Journal of the advanced practitioner in oncology.

Patient- and physician-level determinants of blood pressure response to treatment in normal weight and overweight patients (the PREVIEW study).

I. Abraham, C. Hermans, P. Van der Niepen, 2013, Nutrition, metabolism, and cardiovascular diseases : NMCD.

Antihypertensive effectiveness of aliskiren for the ‘real‐world’ management of hypertension: multilevel modelling of 180‐day blood pressure outcomes (the Belgian DRIVER Study)

I. Abraham, C. Hermans, K. MacDonald, 2011, International journal of clinical practice.

International Journal of General Medicine Dovepress Dovepress 163 R a P I D C O M M U N I C at I O N

C. Hermans, K. MacDonald, S. Vancayzeele, 2022 .

Modelling of blood pressure outcomes in patients with and without established cardiovascular or renal disease following treatment with valsartan (the PREVIEW study).

I. Abraham, C. Hermans, K. MacDonald, 2013, Archives of cardiovascular diseases.

Modelling of blood pressure and total cardiovascular risk outcomes after second-line valsartan therapy: the BSCORE study.

Yu-ming Shen, R. Lins, I. Abraham, 2011, Archives of cardiovascular diseases.

Gender-specific, multi-level determinants of outcomes of antihypertensive treatment: a sub-analysis of the Belgian PREVIEW study

I. Abraham, C. Hermans, K. MacDonald, 2011, Journal of Human Hypertension.